Drug Discovery

resTORbio raises $40m from biotech and institutional investors

resTORbio, a clinical-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of aging-related diseases, has raised $40m in a Series B financing round.

Biogen, Alkermes to develop and commercialize ALKS 8700 to treat multiple sclerosis

Biogen and Alkermes have entered into a global license and collaboration agreement to develop and commercialize ALKS 8700, a novel, oral, monomethyl fumarate (MMF) small drug molecule in phase 3 development for the treatment of relapsing forms of multiple sclerosis (MS).

Research finds gastric acid suppressant lansoprazole could target tuberculosis

A new research in the UK suggests that a cheap and commonly used drug to treat heartburn, gastritis and ulcers has the potential to target Mycobacterium tuberculosis, the bacteria that causes tuberculosis (TB).

Hemogenyx, University of Oxford partner to transform blood cancers treatment

Hemogenyx Pharmaceuticals has partnered the University of Oxford to test new means of accelerating and improving the process by which transplanted blood stem cells grow and make healthy blood cells.

Canadian researchers discover medication to treat amyotrophic lateral sclerosis

Canadian researchers have discovered an effective medication for the treatment of individuals with amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease.

Inozyme Pharma secures $49m funding for rare disease therapies

Inozyme Pharma, which is developing novel medicines to treat rare diseases of calcification, affecting soft tissues and bone, has raised a $49m Series A financing.

Purdue Pharma to invest in oncology research and development

Purdue Pharma says that it has finalized major oncology related investments as part of its move to diversify its scientific research into areas of high unmet medical need.

Bayer and Loxo Oncology to develop and commercialize two cancer therapies

Bayer has entered into an exclusive global collaboration with Loxo Oncology for the development and commercialization of larotrectinib (LOXO-101) and LOXO-195.

Research indicates potential treatment for autism and intellectual disability

A University of Nebraska Medical Center researcher and his team at the Munroe-Meyer Institute (MMI) made a breakthrough in finding the mechanism and a possible therapeutic fix for autism and intellectual disability